Current status of therapeutic monoclonal antibodies against SARS-CoV-2
Open Access
- 3 September 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 17 (9), e1009885
- https://doi.org/10.1371/journal.ppat.1009885
Abstract
No abstract availableKeywords
Funding Information
- Indian Council of Medical Research (VIR/COVID-19/02/2020/ECD-1)
- Indian Council of Medical Research (VIR/COVID-19/02/2020/ECD-1)
- The Wellcome Trust DBT India Alliance (IA/E/18/1/504307)
This publication has 42 references indexed in Scilit:
- An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19JAMA, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19The New England Journal of Medicine, 2021
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategiesNature, 2020
- Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus CompoundsViruses, 2020
- CoV-AbDab: the coronavirus antibody databaseBioinformatics, 2020
- A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 InfectionThe Journal of Immunology, 2020
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibodyNature, 2020
- A human monoclonal antibody blocking SARS-CoV-2 infectionNature Communications, 2020
- Developing therapeutic monoclonal antibodies at pandemic paceNature Biotechnology, 2020